• Philipp Beckhove, Olaf Oberschmidt, Axel R Hanauske, Clara Pampillón, Volker Schirrmacher, Nigel J Sweeney, Katja Strohfeldt, and Matthias Tacke.
• Deutsches Krebsforschungszentrum, Abteilung Zelluläre Immunologie, Heidelberg, Germany.
• Anticancer Drugs. 2007 Mar 1; 18 (3): 311-5.

AbstractBis-[(p-methoxybenzyl)cyclopentadienyl] titanium dichloride, better known as Titanocene Y, is a newly synthesized transition metal-based anticancer drug. We studied the antitumor activity of Titanocene Y with concentrations of 2.1, 21 and 210 micromol/l against a freshly explanted human breast cancer, using an in-vitro soft agar cloning system. The sensitivity against Titanocene Y was highly remarkable in the breast cancer tumor in the full concentration range. Titanocene Y showed cell death induction at 2.1 micromol/l, well comparable to cisplatin, given at a concentration of 1.0 micromol/l. A further preclinical development of Titanocene Y was warranted and therefore an MCF-7 human breast cancer xenograft nonobese diabetic/severe combined immunodeficient mouse model was used. Titanocene Y was given for 21 days at 30 mg/kg/day (75% of the maximum tolerable dose of Titanocene Y), which resulted in the reduction of the tumor volume to around one-third, whereas no mouse was lost because of the surprisingly low toxicity of Titanocene Y.

20 keywords...

hide…